anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil vehicle delivery system are as therapeutically effective in man and animals as the corresponding higher concentrations of ophthalmic drugs that are commercially used in aqueous solutions. Eye drops that utilize this nonaqueous oil delivery system, when used in man, are comfortable to use and produce little ocular irritation, have a longer shelf-life, low systemic toxic potential, and only short term blurring of vision. Using this nonaqueous oil delivery system, a single drop of ophthalmic drug with a concentration that is 10 times less than the same drug used in commercially available aqueous eye drops is as effective as the commercially available aqueous ophthalmic eye drops that require many applications to be effective. In addition, utilizing the nonaqueous oil delivery system as eye drops produces no ocular sensation of burning, stinging or excessive tearing that is commonly associated with the commercially available aqueous eye drops. This very dilute ophthalmic drug preparation has a greatly reduced systemic toxicity potential as compared to the commercially used aqueous ophthalmic drops. The vehicle includes castor oil, corn oil, glycerol, mineral oil USP, vegetable oil, white petrolatum USP, and mixtures, there of. The ophthalmic class of drugs includes antimicrobials, miotics, mydriatics, mydriatic-cycloplegics, mydriatic-cycloplegic reversal agents and topical anesthetics.
FIELD: medicine. SUBSTANCE: method involves administering Roncoleukine on the background of basic therapy using ultrasonic inhalator unit or nebulizer at a dose of 250000 MU with 48-72 h long pauses between the inhalation procedures. Roncoleukine is subcutaneously administered concurrently with inhalation course. The total treatment course is 2-3 procedures long. EFFECT: enhanced effectiveness of treatment. 4 tbl
Ambulant children with cerebral palsy between 6 and 17 years old with a consistent gait pattern. They have prescribed ankle-foot orthoses by the medical team as part of the standard care.
Systems and methods of automatically or semi-automatically loading patient chart information onto a patient room computer system. The systems and methods involve using the patient room computer system to obtain patient identifying information, then requesting the patient chart from a primary computer system. Upon receiving the patient chart from the primary computer system, the invention relates to displaying the patient chart on the patient room computer system. Obtaining the patient information may occur in several ways. For instance, since a patient is typically associated with a specific room within the healthcare facility, the act of obtaining patient information may involve determining the room identification for the patient and using the room identification, requesting the patient chart associated with the room. In an embodiment, the room identification information is transmitted to the patient room computer system automatically upon entering the room, e.g., by using cellular telephone technology. In another embodiment, the patient room computer system has bar-code reading capabilities and thus reads a bar-code, either as part of the room providing room information as part of the patient providing patient identification information independent of room information.
Glucose metabolism is a crucial biological pathway maintaining the activation of extra- and intracellular signaling pathways involved in the immune response. Immune cell stimulation via various environmental factors results in their activation and metabolic reprogramming to aerobic glycolysis. Different immune cells exhibit cell-type-specific metabolic patterns when performing their biological functions. Numerous published studies have shed more light on the importance of metabolic reprogramming in the immune system. Moreover, this knowledge is crucial for revealing new ways to target inflammatory pathologic states, such as autoimmunity and hyperinflammation. Here, we discuss the role of glycolysis in immune cell activity in physiological and pathological conditions, and the potential use of inhibitors of glycolysis for disease treatment.
Divalproex sodium extended-release tablets are administered orally. The recommended initial dose is 25 mg/kg/day given once daily. The dose should be increased as rapidly as possible to achieve the lowest therapeutic dose which produces the desired clinical effect or the desired range of plasma concentrations. In a placebo-controlled clinical trial of acute mania or mixed type, patients were dosed to a clinical response with a trough plasma concentration between 85 and 125 mcg/mL. The maximum recommended dosage is 60 mg/kg/day.

There is no body of evidence available from controlled trials to guide a clinician in the longer term management of a patient who improves during divalproex sodium extended-release tablets treatment of an acute manic episode. While it is generally agreed that pharmacological treatment beyond an acute response in mania is desirable, both for maintenance of the initial response and for prevention of new manic episodes, there are no data to support the benefits of divalproex sodium extended-release tablets in such longer-term treatment (i.e., beyond 3 weeks).
Patients receive abemaciclib PO BID on days 1-7 and gemcitabine IV, over 90 minutes, on day 10 of each cycle. Cycles repeat every 21 days, for up to 2 years of total treatment, in the absence of disease progression or unacceptable toxicity. Patients may change to cohort I treatment schedule once the recommended schedule is determined. Patients may undergo tumor biopsy during screening and PET scan and blood sample collection throughout the study.
Invasive group A streptococcal (iGAS) infection is a leading cause of maternal death. The increase in the number of patients with iGAS in Japan is markedly greater than before the coronavirus pandemic. We encountered a case of iGAS infection, on a remote island with restricted medical resources, in a third-trimester pregnant woman, resulting in both maternal and fetal death. A 34-year-old woman was admitted via a local general hospital with a high fever. Intrauterine fetal death disseminated intravascular coagulation, and septic shock were confirmed. Broad-spectrum antibiotics were started, and the patient was returned to the local general hospital. Eight hours after arrival, the patient died of circulatory and respiratory dysfunction complications. iGAS infections in remote areas may directly lead to life-threatening conditions and should be treated as an emergency, comparable to the serious conditions of placental abruption or placenta previa.
INTRODUCTION: Inguinal hernia management in patients with diabetes mellitus (DM) and comorbidities presents challenges due to potential impacts on wound healing and infection risk. This study evaluates the influence of additional comorbidities on outcomes following open inguinal hernia repair in DM patients.
MATERIAL AND METHODS: A retrospective cohort study was conducted at Craiova Emergency Clinical County Hospital from 2015 to 2020. Patients with documented DM undergoing hernia repair were categorized into two groups based on comorbidity status. Data on presentation mode, hernia type, comorbidities, hospitalization, operative details, postoperative outcomes, and costs were collected and analyzed statistically.
RESULTS: Among 38 DM patients undergoing hernia repair, 16 were in Group A (DM alone) and 22 in Group B (DM with comorbidities). Group B patients were older (p = 0.0002) and more likely to present emergently (OR: 13.81, p=0.0148) with incarcerated (OR: 22.733, p=0.0339) or strangulated hernias (OR: 9.4545, p=0.0390). Group B had longer hospitalizations (p=0.00132) and higher hospitalization costs (p = 0.00262).
CONCLUSIONS: DM patients with comorbidities are at higher risk for complex hernias and prolonged hospitalizations. Pulmonary fibrosis emerges as a significant comorbidity requiring specific perioperative strategies. Tailored preoperative assessments and care plans can optimize outcomes.
FIELD: new medical agent intended to normalize immune status of organism. SUBSTANCE: antiinflammatory and antimicrobial agent - chlobasol - is used in the capacity of immunomodulator, particularly for treatment of chronic bronchitis with derangements of immune status. Chlobasol is administered at the rate of one tablet (0.1 g) three times a day for 14 days. As compared with known immunomodulator (levamisol), chlobasol features not only immunocorrecting but also antiinflammatory and antimicrobial effect. As distinct from levamisol, it is not toxic. EFFECT: new antiinflammatory and antimicrobial agent - chlobasol - is used in a new function, as immunomodulator.
Based on positive research with divalproex in children/adolescents with autism, we would like to extend this research to autistic adults with high levels of aggression, irritability, affective instability, or agitation. We aim to have 10 adult autistic patients enrolled in our study of the treatment of aggression/irritability with divalproex sodium ER. This will be an open treatment for adult patients to determine if the tolerability of divalproex sodium is better with the extended release. We propose this open label design because previous double-blinded studies of divalproex sodium were only done in children, not adults. These results will serve as pilot data for a future blinded study for autistic adults with the extended release formulation. This naturalistic design will allow for prior stable (3 months) use of concomitant medications. Our objective is to determine how well these patients can tolerate the prescribed doses and what added benefits can be attributed to divalproex sodium ER.
FIELD: medicine.SUBSTANCE: invention relates to medicine, dentistry, reflexology and medical rehabilitation and can be used to treat patients with pain-dysfunction syndrome of the temporomandibular joint (TMJ). Perform reflex-medication effect on biologically active points (BAP). After treatment with an antiseptic solution, a solution of an antihomotoxic preparation of Traumeel 0.2–0.6 ml per one point pre-dialed into a syringe with a needle for pharmacopuncture or mesotherapy is injected into a projection of the BAP selected with regard to the location of the pain zones in the masticatory musculature. In the presence of painful points in the masticatory muscle (m. Masseter), medial and lateral pterygoid muscle, the drug is injected into the points IG 17, 18; E 5, 6, 7; VB 3; TR 22. In the presence of painful points in the anterior and middle portions of the temporal muscle, the drug is injected into the points E 8, VB 4, 5, 6, 7, 13. With pain in the back portion of the temporal muscle, the drug is injected into the points VB 8, 9, 10. First, the drug is injected into the points on the side of the pain zone, then to the symmetrical points on the contralateral side. Treat the TMJ zone with antiseptic solution and with the help of the second syringe prefilled with medication Target T. Inject this drug in a dose 0.2–0.5 ml in BAP VB 2; IG 19; TR 21, 22. Also affects the symmetrical points: first — on the side of the pain, then — on the contralateral side. Number of points used in one procedure is 8–14. Course of treatment is 10–15 procedures, every other day.EFFECT: method provides a reduction in treatment time, rapid regression of clinical symptoms, no side effects, lengthening remission as a result of pathogenetically justified effects directly on the TMJ, enhancement and accelerating the appearance of the therapeutic effect and prolonging the result.1 cl, 2 ex
Patient will be given the Fitbit device and instructed on how to use it. They will be given their username and password to the Fitbit device, and instructed on how to interact with other patients in the study as well as the coordinator on the Fitbit website. The coordinator will also show the patient how to install the application on a smart phone device and use the device via smartphone. The patient will then be instructed to walk as far as they can each day for a period of 12 weeks. Patients will check their steps daily and interact with other patients who participate in the study. Patients will return for a 3 month follow-up appointment where they will undergo a redo 6 minute walk test and questionnaires.
Natural killer (NK) cells recognize and may kill malignant cells via their cell surface receptors. Killer cell immunoglobulin-like receptor (KIR) genotypes of donors have been reported to adjust the risk of relapse after allogeneic stem cell transplantation (HSCT), particularly in patients with acute myeloid leukemia. To test whether non-KIR NK cell receptors have a similar effect, we screened 1,638 genetic polymorphisms in 21 non-KIR NK cell receptor genes for their associations with relapse and graft-versus-host disease (GVHD) after HSCT in 1,491 HSCT donors (from Finland, the UK, Spain, and Poland), divided into a discovery and replication cohort. Eleven polymorphisms regulating or located in CD226, CD244, FCGR3A, KLRD1, NCR3, and PVRIG were associated with the risks for relapse and GVHD. These associations could not be confirmed in the replication cohort. Blood donor NK cells carrying alleles showing genetic protection for relapse had a higher in vitro NK cell killing activity than non-carriers whereas those with alleles genetically protective for GVHD had lower cytotoxicity, potentially indicating functional effects. Taken together, these results show no robust effects of genetic variation in the tested non-KIR NK cell receptors on the outcome of HSCT.
Sleep disturbances in children with epilepsy are prevalent, and are associated with substantial adverse medical and psychosocial consequences. This study is a 5-year follow-up of a clinic-based sleep intervention study that randomized 100 toddlers and preschool-age children with epilepsy to a usual care group or a sleep intervention group. The intervention group received standard paediatric neurology care plus three education sessions during the child's routine clinic visit. The outcomes measured were: (1) child sleep by actigraphy and parental report; and (2) maternal sleep and depression. We aimed to evaluate the long-term benefits of a clinic-based sleep intervention for paediatric epilepsy. In total, 42 families (42.0%) participated. The average child's age at follow-up was 9.55 years. Thirty-eight (90.5%) children were not obtaining sufficient sleep at baseline, and 40 (95.2%) at the 5-year follow-up. The numbers of children with clinically significant sleep disturbances were 40 (95.2%) at baseline and 36 (85.7%) at the 5-year follow-up. Fourteen mothers (33.3%) had poor sleep quality and high depressive symptoms at both assessment time points. There were no differences (P > 0.05) in the child and maternal outcomes between the two trial arms. Overall, there was no evidence that a clinic-based sleep intervention that effectively improved multiple aspects of sleep in toddlers and preschool-age children with epilepsy had long-lasting beneficial effects. Our findings suggest that sleep interventions for families of children with epilepsy require ongoing reinforcement and monitoring during routine paediatric neurology care to prevent sleep problems from persisting or recurring.
The present invention relates to an oral alcohol-relieving liquid and a preparation method thereof, which belongs to the technical fields of health foods and beverages and the preparation method thereof. The present invention needs to achieve the purpose of providing an oral alcohol-relieving liquid with favorable alcohol-relieving effect, no toxic or side effect on human bodies and no damage to human bodies. The present invention has the technical key point that the liquid comprises the raw material compositions: 20 to 30 wt% of ginger, 4 to 8 wt% of amomun fruit, 2 to 7 wt% of white cardamom, 4 to 8 wt% of orange peel, 1 to 5 wt% red bean, 2 to 6 wt% of liquorice, 1 to 4 wt% of betel nut, 0.1 to 0.4 wt% of male clove and 40 to 60 wt% of honey. The formula has precise combination, does not comprise any western medicine or chemosynthesis substance, and has the functions of inducing resuscitation, strengthening eyesight, warming middle energizer to promote qi, clearing stomachs, preventing vomit, removing toxicity, promoting urination, etc. Pharmacological experiments and clinical probation prove that the oral alcohol-relieving liquid has the function of relieving alcohol on drunkenness gaffes caused by excessive drinking and has the function of preventing vomit caused by excessive drinking, or carsickness or seasickness. The oral liquid has the function of preventing drunkenness when used as a banquet health-care beverage, and has little toxicity.
Dose Arm 4 (phase II): SSGJ-613 200 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh. Randomized patients will receive one s.c. injection of SSGJ-613 and placebo matching compound betamethasone injection (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection is recommended to be administered deeply into the gluteal muscle.
A stent for implantation into a blood vessel of a patient to maintain the patency of the blood vessel is disclosed. The stent comprises a series of rings (12.1) each composed of bars (16.1, 18.1) arranged zig-zag fashion and joined at their ends by hairpin bends (20.1). The rings are joined by longitudinals. The configuration of the bars and hairpin bends is such that, in the circumferential direction, dimension W3 is less than W2, and dimension W2 is less than W1, which latter dimension is measured in the axial direction. From the larger dimension portion at W2 to the smaller dimension portion at W3, each bar (16.1, 18.1) tapers smoothly without steps or other discontinuities. Recesses or holes (22, 24) can be provided in which drugs can be placed for release into the patient's blood stream.
Parenteral drug products should be inspected visually prior to administration whenever the solution and the container permit. LANTUS must only be used if the solution is clear and colorless with no particles visible.

Mixing and diluting: LANTUS must NOT be diluted or mixed with any other insulin or solution [S . ee ] Warnings and Precautions (5.2)

The syringes must not contain any other medicinal product or residue. Vial:

: If SoloStar disposable insulin device, malfunctions, LANTUS may be drawn from the cartridge system or from SoloStar into a U-100 syringe and injected. SoloStar
PURPOSE:To readily prepare a liniment and carry out hemostasis of incised wounds with rapid action thereon at a low cost by adding common salt to young buds of mugwort, thoroughly kneading the mixture and applying the kneaded mixture onto the incised wounds. CONSTITUTION:Young buds of mugwort ('MOCHIGUSA' (used in rice cake mixed with leaves thereof)) naturally growing in Japan from HOKKAIDO to OKINAWA are picked and common slat is added to thoroughly knead the mixture. The resultant kneaded mixture is then applied onto incised wounds to carry out hemostasis thereof. For example, 10g common salt is added to 100g leaves of the mugwort and rubbed therein by hand. The mugwort is held by both hands, rubbed and gradually softened to provide a somewhat rice caky state with some generated moisture. The obtained material is then tapped by palms of both hands, formed into the shape of Japanese cracker and applied to an affected part. The hemorrhage is instantly stopped by applying the material to the affected part. The obtained liniment is effectively used as a household medicine.
The present invention is directed to flagellin and its use as an adjuvant for vaccination. Preferably, flagellin is membrane bound, which might be achieved by using the mammalian surface display plasmid pDisplay. The invention can be used in vaccine formulations to improve immunity against any other antigen administered at the same localization. The antigen can be administered in the same construct as flagellin or in any other formulation given at the same localization. As an alternative flagellin can be used to stimulate immunity against antigens expressed at a specific location. Flagellin can also be used to induce local inflammation with the purpose of creating a model for inflammation.
Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.
The participant who is randomly assigned to this group completes The Power as Knowing Participation in Change Version II (PKPCT) to determine 1.) Freedom to Act Intentionally, 2.) Involvement in Creating Change, 3.) Freedom to Act Intentionally and 4.) My Involvement in Creating Change.
Several regulatory agencies continue to require animal feeding studies to approve new genetically modified crops despite such studies providing little value in the safety assessment. Feeding studies with maize grain containing event DP-915635-4 (DP915635), a new corn rootworm management trait, were conducted to fulfill that requirement. Diets fed to Crl:CD®(SD) rats for 90 days contained up to 50% ground maize grain from DP915635, non-transgenic control, or non-transgenic reference hybrids (P1197, 6158, and 6365). Ross 708 broilers received phase diets containing up to 67% maize grain from each source for 42 days. Growth performance was compared between animals fed DP915635 and control diets; rats were further evaluated for clinical and neurobehavioral measures, ophthalmology, clinical pathology, organ weights, and gross and microscopic pathology, whereas carcass parts and select organ yields were determined for broilers. Reference group inclusion assisted in determining natural variation influence on observed significant differences between DP915635 and control groups. DP915635 maize grain diet consumption did not affect any measure evaluated in either feeding study. Results demonstrated DP-915635-4 maize grain safety and nutritional equivalency when fed in nutritionally adequate diets, adding to the existing literature confirming the lack of significant effects of feeding grain from genetically modified plants.
Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K \< 4.0 mEq/L, and patiromer will be discontinued if K \< 3.5 mEq/L.
Idarubicin was embryotoxic and teratogenic in the rat at a dose of 1.2 mg/m2/day or one tenth the human dose, which was nontoxic to dams. Idarubicin was embryotoxic but not teratogenic in the rabbit even at a dose of 2.4 mg/m2/day or two tenths the human dose, which was toxic to dams. There is no conclusive information about idarubicin adversely affecting human fertility or causing teratogenesis. There has been one report of a fetal fatality after maternal exposure to idarubicin during the second trimester.

There are no adequate and well-controlled studies in pregnant women. IDAMYCIN PFS should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. If IDAMYCIN PFS is to be used during pregnancy, or if the patient becomes pregnant during therapy, the patient should be apprised and informed of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid pregnancy. Women of childbearing potential should be advised to use effective contraception during treatment with IDAMYCIN PFS and for 6.5 months after the last dose. Men with female partners of childbearing potential should be advised to use effective contraception during treatment with IDAMYCIN PFS and for 3.5 months after the last dose. Both men and women should seek advice for fertility preservation before treatment and/or seek genetic counselling after treatment.